Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bonesupport Holding ABBOEUF 77 EV-to-EBIT is 41.39 as of Jul. 24, 2026. GuruFocus rates BOEUF with a GF Score™ of 77/100 and a GF Value™ of $42.97 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 465 Medical Devices & Instruments companies, Bonesupport Holding AB ranks worse than 83.44% on this metric.
Bonesupport Holding AB (OTCPK:BOEUF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bonesupport Holding AB's Enterprise Value for the quarter that ended in Jun. 2026 was $1,356.8 Mil.
Bonesupport Holding AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $32.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bonesupport Holding AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonesupport Holding AB EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonesupport Holding AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bonesupport Holding AB's EV-to-EBIT falls into.
Bonesupport Holding AB's current Enterprise Value is $1,363.0 Mil.
Bonesupport Holding AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $32.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonesupport Holding AB (BOEUF) has a EV-to-EBIT of 41.39 as of Jul. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bonesupport Holding AB and its competitors. According to the industry distribution chart, Bonesupport Holding AB ranks #388 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 83.4%.
Is Bonesupport Holding AB's EV-to-EBIT too high?
Bonesupport Holding AB's current EV-to-EBIT is 41.39. The Medical Devices & Instruments industry median EV-to-EBIT is 18.24. Bonesupport Holding AB's value of 41.39 is 126.9% above this industry median. Based on the distribution chart, Bonesupport Holding AB ranks #388 out of 465 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bonesupport Holding AB has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bonesupport Holding AB's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bonesupport Holding AB ranks #388 out of 465 companies for EV-to-EBIT. This places Bonesupport Holding AB in the lower half of its industry. The industry median EV-to-EBIT is 18.24. Bonesupport Holding AB's value of 41.39 is 126.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.24, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonesupport Holding AB's current EV-to-EBIT of 41.39 is 126.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bonesupport Holding AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonesupport Holding AB's current EV-to-EBIT is 41.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonesupport Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Bonesupport Holding AB (BOEUF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.97, compared to a current price of $20.49 — trading 52.3% below its estimated fair value. The current EV-to-EBIT is 41.39 and 126.9% above the Medical Devices & Instruments industry median of 18.24. Bonesupport Holding AB's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bonesupport Holding AB (BOEUF), the current EV-to-EBIT is 41.39 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonesupport Holding AB (BOEUF) Overvalued in 2026?
Based on GuruFocus' analysis, Bonesupport Holding AB stock appears to be undervalued.
The current stock price of $20.49 is trading 52.3% below its estimated GF Value™ of $42.97.
GuruFocus considers Bonesupport Holding AB to be Significantly Undervalued.
Key valuation signals for BOEUF:
EV-to-EBIT: 41.39
GF Value™: $42.97 vs. price of $20.49 (52.3% below fair value)
Industry Position: 126.9% above the Medical Devices & Instruments median (#388 of 465)
No single metric tells the full story. See the BOEUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonesupport Holding AB is a fast-growing ortho-biologics company that focuses on the treatment of bone disorders. The Company develops and commercializes injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and can release pharmaceuticals to promote healing. The products of the company focus on trauma, revision arthroplasty (replacement of joint prostheses), chronic osteomyelitis (bone infection), and foot and ankle surgery. The Group manages and monitors operations in two operating segments: United States and Europe & Rest of the World (EUROW).
77GF Score
Get the complete analysis for BOEUF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOEUF has been successfully added to your 
